Draupnir Bio is developing oral small molecule degraders that utilize lysosomal machinery to target and eliminate extracellular pathogenic proteins, addressing the need for effective treatments in cholesterol metabolism and cardiovascular disease. Their proprietary technology platform aims to revolutionize targeted protein degradation by specifically targeting lysosome receptors, potentially reducing the risk of heart-related complications.
Funding
$63.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
EAMHFounders
Product
Problem
Current treatments for cardiovascular diseases and cholesterol metabolism disorders often fail to effectively target and eliminate extracellular pathogenic proteins. Existing therapies may also have limitations in terms of delivery, specificity, and potential side effects. There is a need for novel approaches that can selectively degrade these disease-causing proteins to improve patient outcomes.
Solution
Draupnir Bio is developing oral small molecule degraders designed to target and eliminate extracellular pathogenic proteins via the lysosomal pathway. Their proprietary technology platform focuses on lysosome receptors to facilitate targeted protein degradation. This approach aims to offer a more selective and effective method for addressing diseases related to cholesterol metabolism and cardiovascular health. By utilizing the body's natural cellular machinery, Draupnir Bio's technology has the potential to reduce the risk of heart-related complications associated with current treatment options. The oral delivery method offers a convenient alternative to traditional injectable therapies.
Target Audience
The primary target audience includes patients with cardiovascular diseases and cholesterol metabolism disorders, as well as pharmaceutical companies seeking innovative therapeutic approaches in these areas.
Features
- Oral small molecule degraders for convenient administration
- Targets extracellular pathogenic proteins implicated in cardiovascular disease
- Utilizes the lysosomal pathway for protein degradation
- Proprietary technology platform targeting lysosome receptors
- Selective degradation of target proteins to minimize off-target effects